Previous 10 | Next 10 |
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led trial evaluating TRV027 currently enrolling COVID-19 patients Cleveland Clini...
CHESTERBROOK, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of an exploratory...
CHESTERBROOK, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financia...
Score Media and Gaming (NASDAQ:SCR) +65% Penn National Gaming inks deal to acquire Score Media and Gaming Ensysce Biosciences (NASDAQ:ENSC) +38% announces notice of allowance from the U.S. Patent and trademark office for Patent entitled “compositions comprising enzyme-cl...
Shares of Trevena Inc. (NASDAQ:TRVN) traded at a new 52-week low today of $1.41. Approximately 423,000 shares have changed hands today, as compared to an average 30-day volume of 2.9 million shares. Trevena Inc. share prices have moved between a 52-week high of $3.68 and the current low ...
CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that the first COVID-19 patient h...
CHESTERBROOK, Pa., July 23, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Glass Lewis and ISS, two ind...
Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and com...
Keymed Biosciences of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidate. I-Mab announced two partnerships to develop oncology candidates with China biopharmas that offer novel discovery technologies. Eucure Biopharma has been approved ...
Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China CHESTERBROOK, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (N...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...